PMID int64 27.8M 36.2M | Title/Abstract stringlengths 7 10.7k | MeshTerms stringlengths 7 104 | SemanticTypes stringlengths 4 84 |
|---|---|---|---|
34,677,244 | frontlin treatment young fit patient cll canadian perspect canadian perspect limit discuss frontlin manag young fit patient chronic lymphocyt leukemia cll preval popul rang per person canada vari region recent fix durat fludarabin base chemoimmunotherapi cit primari treatment option canada patient popul ecog trial sinc demonstr ibrutinib rituximab therapi effect fludarabin cyclophosphamid rituximab fcr popul allianc trial show rituximab ad increment benefit ibrutinib canadian payor physician adopt ibrutinib monotherapi cll standard care even young fit popul although frontlin ibrutinib therapi often reimburs provinci public drug plan patient high risk diseas unfit receiv fludarabin young fit patient cll physician may choos continu ibrutinib monotherapi fix durat cit fcr factor affect choic includ patient prefer short long term toxic profil regimen risk base algorithm provid new continu therapi option enter market treatment choic present benefit risk must communic patient | D015451 | T191 |
34,677,243 | surviv outcom associ first second line palliat system therapi patient metastat bladder cancer real world data palliat system therapi pst treat metastat bladder cancer mbc limit studi investig current trend treat mbc first l second line l chemotherapi ct immunotherapi | D001749 | T191 |
34,677,242 | feasibl stereotact bodi radiat therapi unresect stage iii nsclc peripher primari tumor prospect studi gfpc concomit radiochemotherapi rtct standard treatment unresect stage iii non small cell lung cancer nsclc howev patient peripher primari tumor irradi volum may includ larg portion normal lung rt ct possibl multicent phase ii trial unresect stage iii nsclc peripher primari tumor evalu feasibl stereotact bodi radiat therapi sbrt peripher tumor concomit radio chemotherapi rt ct nineteen patient includ analyz median age year male adenocarcinoma median size peripher primari tumor mm month diseas control rate sbrt toxic general mild one patient grade lung toxic recruit studi stop prior complet first due approv adjuv durvalumab rt ct anticip design second due small number stage iii nsclc patient peripher tumor access sbrt nevertheless combin rt ct sbrt appear feasibl safe | D002289;D008175;D016634 | T191;T061 |
34,677,241 | accept psycho oncolog counsel format cancer counsel center covid pandem exploratori care studi covid pandem made necessari chang establish structur medic counsel servic quick establish digit counsel format ensur continu care context offer telephon video telephon counsel addit tradit face face counsel offic | D000086382;D009369 | T191;T047;T067 |
34,677,240 | assess risk bias osteosarcoma ewe sarcoma random control trial systemat review aim studi systemat assess risk bias osteosarcoma ewe sarcoma es random control trial rct examin relationship bias conflict interestindustri sponsorship | D012512 | T191 |
34,677,239 | global dna hmc ck hmc content promis biomark predict prognosi small hepatocellular carcinoma hydroxymethylcytosin hmc dynam exist possess multipl regulatori function wherea hmc impact small hepatocellular carcinoma shcc remain unclear present work focus character hmc content within shcc assess possibl use global genom hmc level predic factor clinic outcom | D006528;D008113 | T191 |
34,677,238 | surgic manag proxim femor metastas narrat review proxim femur common locat develop boni metastat diseas metastat bone diseas locat caus debilit pain patholog fractur reduc qualiti life anemia hypercalcemia thorough histori physic examin preoper investig requir ensur accur diagnosi prognosi goal surgic manag provid pain relief return function construct provid stabil allow immedi weightbear current surgic treatment option includ intramedullari nail hemiarthroplasti total hip arthroplasti endoprosthet reconstruct oligometastat renal cell carcinoma must given special consider tumor resect reconstruct surviv benefit tumor patient characterist must taken account decid appropri surgic intervent | D001859;D011788 | T191;T078 |
34,677,237 | risk factor duodenobiliari reflux relat dysfunct cover biliari metal stent treatment duoden strictur patient malign biliari duoden obstruct duoden obstruct often accompani unresect malign distal biliari obstruct patient undergon biliari self expand metal stent sem placement duodenobiliari reflux dbr major caus recurr biliari obstruct rbo cover biliari sem placement analyz risk factor dbr relat sem dysfunct follow treatment malign duoden obstruct sixti one patient cover sem underw treatment duoden obstruct includ exclud patient tumor relat stent dysfunct n metal stent migrat n fifti four patient underw cover biliari sem placement follow duoden metal stent surgic gastrojejunostomi includ eleven patient dbr relat biliari sem dysfunct treatment duoden obstruct differ duoden metal stent group surgic gastrojejunostomi group duoden obstruct papilla vater score gastric outlet obstruct score system treatment duoden obstruct associ dbr relat cover biliari sem dysfunct thus creat reliabl rout ensur good oral intak avoid dbr patient duoden obstruct papilla vater import factor prevent dbr relat cover biliari sem dysfunct | D002779;D004380 | T047 |
34,677,236 | clinic outcom dose reduc radiotherapi prostat elder patient local prostat cancer radic treatment local prostat cancer elder patient may lead unaccept treatment associ toxic advers impact qualiti life without improv surviv outcom studi report cohort elder year patient receiv cgi palliat extern beam radiotherapi ebrt altern androgen depriv therapi adt primari outcom interest period adt free surviv secondari outcom includ overal surviv os metastas free surviv mfs kaplan meier regress use estim surviv outcom thirti six patient achiev break adt post radiotherapi median time adt reiniti month common terminolog criteria advers event ctcae limit low grade gastrointestin gi genitourinari gu toxic skin toxic observ grade gi toxic observ patient grade gu toxic observ patient respect higher grade toxic report five year mfs os respect summari treatment regimen well toler achiev durabl adt free surviv patient dose reduc ebrt appear viabl altern adt elder patient local prostat cancer | D000726;D011471 | T039;T191;T121 |
34,677,235 | comprehens genom profil circul cell free dna distinguish focal met amplif aneuploidi divers advanc cancer amplif amp met observ case focal gene copi number gain met driven amp gain chromosom aneuploidi sever studi shown high level focal met amp met cep ratio oncogen tumor respond target therapi howev report distinguish focal amplif aneuploidi use next generat sequenc ngs total patient advanc solid tumor typic pre treat test non invas comprehens cfdna ngs panel guardant juli june sinc bioinformat upgrad guardant undergo septemb focal met amp determin independ algorithm use cohort test septemb patient valid perform remain cohort patient met alter alt associ aberr signal found patient among nine differ cancer type common non small cell small cell lung cancer gastroesophag cancer prostat adenocarcinoma among patient test septemb met alt among amp exon skip singl nucleotid variant snvs co alter amp snvs found four sampl among met amp focal accord algorithm met copi number signific higher focal amp compar non focal amp mean copi number vs respect p patient test septemb definit focal met amp detect overal focal amplif base algorithm studi describ approach distinguish focal non focal met amplif use comprehens genom profil cfdna advanc cancer patient focal met amp account met amp found patient divers cancer associ higher plasma copi number clinic studi warrant assess clinic util target therapi tumor focal met amplif detect ngs cfdna | D000073888;D000074141 | T114;T123 |
34,677,170 | challeng manag supracondylar humer fractur children resourc constrain set upper limb fractur quit common children account paediatr fractur common male femal supracondylar humer fractur varieti one common requir oper intervent known associ complic neurovascular injuri well elbow stiff cubitus varus manag fractur absenc basic suitabl imag facil pose great challeng orthopaed surgeon | D006810 | T037 |
34,677,162 | learn surgeon perform tha tka lowest revis rate studi australian orthopaed associ nation joint replac registri long term implant survivorship tha tka involv combin factor relat patient implant use decis make technic perform surgeon unclear factor import reduc proport revis surgeri | D011474;D011475 | T058;T047;T067 |
34,677,161 | eus guid drainag pancreat fluid collect use modifi techniqu cystotom alon without fna needl endoscop ultrasound eus guid drainag pancreat fluid collect pfc involv punctur fine needl aspir fna needl follow tract dilat involv exchang multipl accessori final deploy stent procedur time consum carri risk loss wire access henc technic failur use modifi techniqu f cystotom alon instead fna needl dilat | D004322;D019160 | T060;T061 |
34,677,155 | acut asthma exacerb sar cov vaccin sinovac case report year old femal receiv sever acut respiratori syndrom coronavirus sar cov vaccin coronavac sinovac beij china subsequ experienc chest discomfort comput tomographi perform day vaccin show multipl infiltr lung ground glass shadow lung field fingertip oxygen satur widespread wheez physic examin base find patient hospit preliminari diagnosi drug induc pneumon acut asthma exacerb due sar cov vaccin hospit mgd system steroid time day salbutamol nebul lmin inhal oxygen therapi mgd moxifloxacin intraven administ day one month later thorax comput tomographi scan reveal previous find almost complet regress | D001249;D000086382;D014612 | T116;T047;T121;T129;T067 |
34,677,154 | predict diagnosi prognosi covid diseas blood gas paramet use decis tree machin learn model retrospect observ studi coronavirus diseas covid epidem went histori pandem caus corona virus emerg spread rapid around world differ symptom covid made difficult understand variabl influenti diagnosi cours mortal diseas machin learn model accur assess hidden pattern among risk factor analyz larg dataset quick predict diagnosi prognosi mortal diseas advantag use machin learn model decis support system health servic increas aim studi determin diagnosi prognosi covid diseas blood gas data use chi squar automat interact detector chaid decis tree model one machin learn method subfield artifici intellig studi carri total patient covid n non covid n treat erzincan mengcek gazi train research hospit april march arteri blood gas valu patient obtain hospit registri system total accuracyratio decis tree model predict prognosi diseas diagnosi diseas accord result obtain low ioniz calcium valu mm signific predict need intens care covid patient admiss low carboxyhemoglobin low sodium mm hematocrit methemoglobin valu import biomark diagnosi covid result promis find studi may aid earli diagnosi diseas intens care treatment patient sever studi approv ministri health erzincan univers faculti medicin clinic research ethic committe | D001185;D000086382 | T047;T066;T073;T067;T090 |
34,677,153 | ozon gas appli nebul adjuv treatment lung respiratori diseas due covid infect prospect random trial object studi provid lung disinfect nebul ozon gas distil water oliv oil patient clinic symptom due coronavirus diseas covid studi attempt reduc viral load covid lung patient provid faster respons medic treatment august septemb patient met studi criteria prospect evalu group patient group patient control group treat ozon receiv standard covid treatment patient ozon group receiv lung disinfect techniqu ozon standard covid treatment statist signific differ found length stay hospit chang c reactiv protein polymeras chain reaction result day comput tomographi score two group statist signific differ dimer urea lactat dehydrogenas lymphocyt leukocyt platelet two group accord data think lung disinfect techniqu appli ozon inhal reduc rate pneumonia covid patient make patient respond faster treatment becom negat accord polymeras chain reaction test studi approv ethic committe istanbul medipol univers clinic trial approv juli | D000086382;D010126 | T047;T103;T067 |
34,677,152 | covid danger older peopl sever increas case control studi coronavirus diseas covid trigger import chang routin blood test retrospect case control studi biochem hematolog inflammatori biomark march novemb covid patient non intens care unit non icu group icu group analyz divid three group spring summer autumn non icu group lymphocyt monocyt ratio lower autumn two season neutrophil lymphocyt ratio higher autumn two season also monocyt platelet higher spring autumn eosinophil hematocrit hemoglobin lymphocyt red blood cell decreas spring autumn non icu group alanin aminotransferas gamma glutamyltransferas gradual increas spring autumn albumin alkalin phosphatas calcium total bilirubin total protein gradual decreas addit c reactiv protein higher autumn season erythrocyt sediment rate higher autumn summer chang routin blood biomark covid vari emerg diseas also time chang blood biomark most negat indic diseas progress sever studi approv erzincan binali yildirim univers non intervent clinic trial ethic committe approv june | D000086382 | T047;T067 |
34,677,151 | effect iranian polyherb syrup zufa syrup oxygen satur clinic symptom suspect patient covid tripl blind random placebo control trial coronavirus diseas covid pandem caus urgent need investig potenti treatment tradit medicin offer mani potenti remedi histor use advantag bypass cultur obstacl practic medicin aim investig efficaci zufa syrup treatment suspect patient mild moder symptom covid tripl blind random control trial recruit patient evid covid chest comput tomographi without indic hospit admiss march april particip assess physician complet pre specifi form assess durat sever symptom patient random receiv zufa syrup combin herbal medicin nepetabracteata ziziphus jujub glycyrrhizaglabra ficuscarica cordia myxa papav somniferum fennel adiantumcapillus veneri viola viper bugloss lavend iri sugar ident look placebo syrup dose ml one tablespoon everi hour day appli elig criteria patient male random trial arm mean age follow cough dyspnea headach myalgia anorexia anxieti insomnia improv gradual group show differ zufa syrup placebo oxygen satur puls rate stabl trend throughout follow similar studi arm patient requir hospit admiss supplement oxygen therapi studi period conclud patient mild moder symptom covid zufa syrup show differ symptomatolog day period compar placebo due potenti effect medicin plant treatment respiratori infect studi warrant clarifi role covid studi approv ethic committe qom univers medic scienc ethic committe refer number irmuqrec march regist iranian clinic trial center approv id irctn april | D000086382 | T047;T067 |
34,677,150 | periop melatonin covid patient benefit beyond sedat analgesia cytokin storm coronavirus diseas covid patient lead acut lung injuri acut respiratori distress syndrom multiorgan dysfunct shock thrombosi thus contribut signific morbid mortal sever agent like steroid ascorb acid vitamin c e glutathion n acetylcystein use sever studi underway identifi efficaci address undesir effect due covid ill among sever experiment modal base expert opinion anecdot data melatonin one molecul appear promis owe anti inflammatori anti oxid immunomodulatori properti melatonin import agent use compon multimod analgesia covid patient suspect patient patient exposur posit patient undergo emerg urgent surgeri research requir know optim time initi dose durat melatonin adjunct | D000698;D000086382;D008550 | T047;T121;T109;T125;T061;T067 |
34,677,149 | potenti therapeut effect oxygen ozon control covid diseas atmospher ozon produc nitrogen oxid react volatil organ compound sever acut respiratori syndrom coronavirus sar cov genom contain uniqu n termin fragment spike protein allow bind air pollut environ approach review studi ozon effect sar cov virus patient coronavirus diseas covid articl data collect pubm scopus googl scholar databas ozon therapi antivir properti improv blood flow facilit transfer oxygen hypoxem tissu reduc blood coagul phenomena covid patient ozon immunomodulatori effect modul cytokin reduct interleukin interleukin tumor necrosi factor interleukin induct interferon anti inflammatori properti modul nod lrr pyrin domain contain protein inhibit cytokin storm block nuclear factor b stimul nuclear factor erythroid relat factor pathway stimul cellularhumor immunityphagocyt function block angiotensin convert enzym direct oxygen ozon inject oxygen react sever biolog molecul thiol group albumin form ozonoid intraven inject ozon salin signific increas length time person remain hypox rectal ozon protocol rectal ozon insuffl result clinic improv oxygen satur biochem improv fibrinogen dimer urea ferritin ldh interleukin c reactiv protein general mani studi shown posit effect ozon therapi complementari therapi recoveri covid patient find indic system ozon therapi nontox side effect patient | D000086382;D010126 | T047;T103;T067 |
34,677,136 | food market instagram shape adolesc food prefer onlin random trial worldwid obes rate prompt countri enact polici reduc children exposur unhealthi food market polici address onlin advertis practic protect adolesc target given adolesc spend much time onlin critic understand persuas instagram food advertis ad compar tradit food ad strengthen onlin food market polici evid need whether social media ad persuas type ad shape adolesc prefer | D005518;D061108 | T080;T170;T055 |
34,677,135 | automat mobil health arrhythmia monitor detect atrial fibril prospect feasibl accuraci user experi studi atrial fibril af common tachyarrhythmia associ risk stroke detect diagnosi af repres major clinic challeng due af asymptomat intermitt natur novel consum grade mobil health mhealth product automat arrhythmia detect could option long term electrocardiogram ecg base rhythm monitor af detect | D001281;D017216 | T058;T047;T046 |
34,677,131 | audio person health librari clinic visit record patient caregiv healthpal user center design approach provid digit record clinic visit patient emerg strategi promot patient famili engag care advanc natur languag process opportun exist maxim valu visit record patient automat tag key visit inform eg medic test imag linkag trustworthi web base resourc curat audio base person health librari | D017028;D000086825 | T097;T170;T098;T099 |
34,677,128 | elus perspect food thief eurasian jay fail take account point view desir jay hide food eat later | D046109;D020308 | T012 |
34,677,126 | singl synonym nucleotid chang impact male kill phenotyp prophag wo gene wmk wolbachia widespread bacteri endosymbiont anim within arthropod matern transmit bacteria selfish hijack host reproduct process increas relat fit transmit femal one form reproduct parasit call male kill select kill infect male recapitul degre transgen express prophag wo mediat kill wmk gene character genotyp phenotyp landscap wmk induc male kill melanogast use transgen express phylogenet distant wmk homolog induc sex ratio bias close relat homolog exhibit complex phenotyp span death male death death host demonstr altern start codon synonym codon notabl singl synonym nucleotid wmk ablat kill find reveal previous unrecogn featur transgen wmk induc kill establish new hypothes impact post transcript process male kill variat conclud synonym sequenc chang necessarili silent nest endosymbiot interact life death consequ | D013559 | T040;T070 |
34,677,124 | intestin goblet cell sampl deliv lumen antigen regul endocyt uptak transcytosi intestin goblet cell maintain protect epitheli barrier mucus secret yet sampl lumen substanc immun process format goblet cell associ antigen passag gap cellular biolog gap diverg process balanc regul goblet cell remain unknown use high resolut light electron microscopi found mice gap form acetylcholin ach depend endocyt event remark deliveri fluid phase cargo retrograd tran golgi network across cell transcytosi addit expect transport fluid phase cargo endosom multi vesicular bodi lysosom ach also induc goblet cell secret mucin ach induc gap format mucin secret function independ mediat differ receptor signal pathway enabl goblet cell differenti regul process accommod dynam chang demand mucos environ barrier mainten sampl lumen substanc | D057900 | T043 |
34,677,122 | molecular reconstruct recurr evolutionari switch olfactori receptor specif olfactori receptor repertoir exhibit remark function divers protein evolv poor understood analysi extant ancestr reconstruct drosophilid olfactori receptor ionotrop receptor ir famili investig evolut two organ acid sens receptor ira irb despit low amino acid ident identifi common hotspot ligand bind pocket major effect chang specif ir well least two distinct function transit ira evolut moreov show odor specif refin chang addit receptor specif site includ outsid ligand bind pocket work reveal core common determin ligand tune act within epistat alloster network substitut lead function evolut olfactori receptor | D019143 | T038 |
34,677,121 | effect level infect gastrointestin nematod anthelmint treatment milk yield dairi sheep effect gastrointestin nematod infect anthelmint treatment milk yield compar flock low level egg per gram epg partum high level hl faecal egg count reduct test fecrt carri partum compar treat group netobimin untreat group ewe belong flock produc milk ewe hl flock negat correl found mean epg treatment mean milk yield per flock r p howev treat ewe produc milk untreat ewe flock although hl flock treat ewe produc less milk treatment flock even low level infect improv milk yield studi epg partum greater influenc total milk yield anthelmint treatment | D000871;D009348;D009349;D012757 | T204;T047;T121 |
34,677,120 | effect hypnot sever gastrointestin symptom qualiti life individu irrit bowel syndrom current studi aim determin effect hypnot sever gastrointestin symptom qualiti life individu irrit bowel syndrom ib trial studi conduct peopl ib shiraz iran hypnot particip perform hour session intervent group week demograph characterist questionnair gastrointestin symptom rate scale ib qualiti life index use data collect sever gastrointestin symptom particip intervent group signific improv week hypnotherapi individu also signific better qualiti life week hypnotherapi hypnotherapi may benefici reduc gastrointestin symptom improv qualiti life individu ib combin method medicin treatment could effect patient health system journal psychosoci nurs mental health servic | D006990;D043183;D011568 | T091;T047;T061 |
34,677,119 | identifi return work percept peopl serious mental ill qualit studi current qualit studi sought identifi return work rtw percept among peopl serious mental ill smi refer psychiatr hospit affili hamadan univers medic scienc total individu recruit includ work peopl smi famili employ mental health team member particip depth semi structur interview forti interview conduct interview analyz base convent content analysi approach accord two theme found includ need continu work flexibl support strategi first theme includ two categori person oblig socioeconom necess second theme includ three categori cope mental ill request support other cope work condit find reveal need continu work signific effect rtw percept among peopl smi journal psychosoci nurs mental health servic | D001523;D062707 | T033;T048 |
34,677,118 | effect aerob exercis adjunct therapi improv negat symptom cognit impair patient schizophrenia random case control clinic trial current studi aim evalu effect exercis negat cognit symptom simultan evalu brain hippocampus volum patient schizophrenia forti patient schizophrenia random divid two group intervent group addit pharmacolog treatment underw multi session exercis program week begin end studi patient assess cognit status negat symptom use mini mental state examin mmse posit negat syndrom scale panss respect total brain volum hippocampus volum also measur use magnet reson imag overal mean mmse score signific improv time improv greater intervent group compar control group true panss negat score vs absolut hippocampus volum week exercis control group increas respect greater increas volum obtain intervent group statist signific p exercis may associ improv cognit function negat symptom patient schizophrenia howev addit studi warrant journal psychosoci nurs mental health servic | D060825;D012559 | T048 |
34,677,117 | choral sing enrich everyday life peopl mild moder dementia famili caregiv dementia caus substanti suffer affect person famili caregiv cure avail import investig altern therapi improv life individu current studi person dementia pwd recruit special memori clinic sweden engag choral sing intervent hour per week four semest pwd encourag bring famili caregiv session interview data analyz use qualit content analysi choral sing intervent appear becom import social context pwd famili caregiv posit impact relationship mental well mood memori intervent appear act enrich environ particip choral sing intervent pwd famili caregiv simpl mean creat social context improv general well journal psychosoci nurs mental health servic | D003704;D063346 | T097;T048;T054;T055 |
34,677,116 | develop psychometr properti spiritu need assess scale patient covid current mix method exploratori studi aim develop determin psychometr scale assess spiritu need patient coronavirus diseas covid studi perform two stage qualit quantit interview patient covid three theme includ composur mean life global respons form quantit stage content valid achiev comment expert patient total particip complet instrument assess construct valid exploratori factor analysi item four subscal perform indic point likert scale cronbach alpha coeffici rang whole scale composur communic mean life global respons subscal respect intraclass correl coeffici test retest analysi show accept stabil scale spiritu need assess scale covid patient item multi dimension scale robust psychometr properti measur various aspect regard spiritu need patient covid journal psychosoci nurs mental health servic | D000086382 | T047;T067 |
34,677,115 | effect pediatr cancer ident young adult survivor result project reach purpos live cancer profound effect ident among treat adult onset cancer identifi cancer survivor common link posit mental physic health outcom although childhood critic period ident format compar less known ident develop pediatr cancer method one hundr seventi young adult previous treat pediatr cancer enrol project reach prospect cohort studi complet self report measur effect cancer ident eg cancer victim survivor ident frequenc thought cancer health outcom ie anxieti depress health relat qualiti life health behavior ie smoke sun protect exercis bing drink result major particip identifi survivor n survivor ident link signific higher anxieti p wors overal mental health p health outcom behavior particip endors victim ident signific like report bing drink p wors overal mental health p nonvictim frequenc thought cancer effect cancer ident also signific associ health outcom eg frequent thought associ higher anxieti conclus find suggest known relationship ident health outcom adult onset cancer general pediatr cancer clinician assum survivor ident associ better health outcom group | D063425;D009369 | T191;T055 |
34,677,114 | seek ye shall fine attitud toward polit perspect seeker six preregist studi n examin peopl respond copartisan polit perspect seeker polit alli attempt hear share oppon better understand view found north american adult student general like copartisan seeker meta analyt cohen across particip repres avail data point peopl like copartisan perspect seeker seem toler cooper ration like diminish seeker seem valid may even adopt oppon illegitim view particip like copartisan seeker across rang differ motiv guid seeker action consist theoriz like decreas though rare disappear entir seeker lack partisan commit sought especi illegitim belief despit evid rise polit intoler recent decad find suggest peopl nonetheless celebr polit alli toler serious consid oppon view | D001290;D009042 | T080;T078;T041;T055 |
34,677,113 | risk factor asept revis oper treat ankl fractur earli revis rate within month ankl fractur open reduct intern fixat af orif fair low howev remain relev given volum ankl fractur occur annual understand rate complex reoper due technic mechan complic typic report alongsid soft tissu relat problem symptomat hardwar wound dehisc infect limit data identifi risk factor specif revis ankl fractur fixat absenc soft tissu complic understand variabl predispos asept technic mechan failur without confound may provid insight improv patient care | D064386 | T037 |
34,677,112 | associ toxic organochlorin level human serum system lupus erythematosus organochlorin oc group high toxic pesticid known immunotox present work aim studi potenti associ serum residu oc risk develop system lupus erythematosus sle well correl clinic laboratori manifest sampl egyptian sle patient cross section studi conduct patient environment expos oc patient diagnos sle base american colleg rheumatolog acr revis criteria system lupus erythematosus diseas activ index sledai k score calcul stratifi diseas sever blood urin sampl collect measur level oc serolog marker urinari protein frequent detect oc p p dde lindan hexachlorobenzen hcb risk develop sle signific associ detect p p dde hcb b valu respect hexachlorobenzen addit signific associ increas sledai k score polycythemia lindan signific associ hypocomplementemia cardiac manifest sle anemia leucopenia conclus detect oc p p dde hcb associ increas risk sle egyptian patient correl manifest diseas sever | D006843;D008180 | T047;T109 |
34,677,108 | home care deliveri remot patient monitor kidney transplant recipi covid pandem telehealth play critic role respons healthcar organ covid pandem telemedicin offer real time patient provid encount inabl obtain vital sign virtual visit potenti limit remot patient monitor rpm use portabl devic patient home collect electron transmit physiolog data clinician two kidney transplant recipi enrol rpm immedi post transplant period real time monitor physiolog data home rpm combin abil titrat medic result normal blood pressur blood glucos measur six week initi experi demonstr rpm feasibl effect post transplant period expand care opportun remot care model relev ever remot monitor facilit care covid posit transplant patient requir close monitor isol home | D000086382;D006699;D016030;D017216 | T058;T047;T061;T067 |
34,677,107 | predispos factor posttraumat osteoarthr malleolus fractur fixat patient younger year purpos studi identifi risk factor posttraumat osteoarthr oa surgeri ankl fractur patient age year | D064386;D010003 | T047;T037 |
34,677,106 | spatial tempor distanc victim offend factor protect order violat much distanc enough research effect protect order indic margin protect valu victim exploratori studi investig physic distanc tempor distanc victim offend correspond percent protect order violat result indic percent protect order violat reduc virtual zero victim offend live mile apart surpris condit held type contact examin physic telephon cyber studi conclud discuss polici implic find suggest futur research | D019548;D057237 | T068;T098 |
34,677,103 | biolog augment tibiotalocalcan arthrodesi allogen bone block associ high rate fusion orthopaed condit system comorbid occur patient requir bone block tibiotalocalcan ttc arthrodesi made procedur associ higher normal risk nonunion graft collaps hardwar failur amput present novel approach bone block ttc arthrodesi use adjunct osteoinduct agent prolong cours protect weightbear assess could improv histor outcom also evalu efficaci vascular medial femor condyl mfc free flap augment ttc arthrodesi | D001688;D058752;D018380 | T024;T121;T061;T123 |
34,677,102 | vitro ct visual biopsi locat fill core biopsi needl contrast media perform comput tomographi ct guid biopsi procedur non dispos automat biopsi instrument actual cours biopsi needl regist | D003287;D007455 | T130;T121;T196;T123 |
34,677,101 | comparison cytokin profil mesenchym stem cell human adipos umbil cord placent tissu human mesenchym stem cell mscs isol various tissu howev cytokin profil differ msc type remain unclear studi mscs extract adipos umbil cord placent tissu surfac marker express multilineag differenti potenti cytokin secret cell compar isol mscs exhibit similar morpholog surfac marker express howev differ regard differenti potenti adipos mscs mscs exhibit higher potenti adipogenesi osteogen differenti compar umbil cord mscs uc mscs placent mscs p mscs express level cytokin detect data demonstr three msc type abund secret insulin like growth factor bind protein igfbp igfbp tissu inhibitor metalloproteinas timp timp igfbp monocyt chemoattract protein granulocyt coloni stimul factor howev express level vascular endotheli growth factor tumor necrosi factor alpha interleukin il receptor il mscs higher compar uc mscs p mscs moreov express level intercellular adhes molecul growth differenti factor lower mscs kyoto encyclopedia gene genom analysi indic adipocytokin pikakt pathway enrich mscs taken togeth result demonstr mscs differ sourc exhibit differ secret specif factor mscs associ express sever proangiogen factor may improv sourc angiogenesi tissu regener | D059630;D010012 | T025;T042 |
34,677,099 | compar outcom follow endoscop ultrasound guid biliari drainag versus percutan transhepat biliari drainag malign biliari obstruct systemat review meta analysi background aim studi explor efficaci safeti endoscop ultrasound guid biliari drainag eus bd percutan transhepat biliari drainag ptcd patient malign biliari obstruct fail endoscop retrograd cholangiopancreatographi method search pubm embas web scienc cochran central regist control trial central clinicaltrialsgov identifi studi report outcom compar eus bd ptcd result identifi studi involv patient technic success similar eus bd ptcd odd ratio confid interv ci p eus bd associ higher clinic success versus ptcd ci p studi howev signific differ group studi use self expand metal stent ci p report advers event rate signific lower eus bd compar ptcd ci p conclus avail literatur suggest eus bd associ fewer advers event greater clinic success compar technic success compar ptcd accord shortcom studi larg high qualiti random control trial need compar techniqu confirm find | D002779 | T047 |
34,677,098 | disrupt daili routin mediat socioeconom gradient depress amid public health crise repeat cross section studi socioeconom gradient depress risk pronounc inequ amid macroenvironment potenti traumat event mid mid hong kong popul experienc drastic societ chang includ escal civil unrest covid pandem examin chang socioeconom gradient depress potenti intermediari role daili routin disrupt | D000086382;D003863 | T048;T047;T184;T067 |
34,677,097 | predict risk factor convers video assist treatment anal fistula seton fistulotomi background identifi risk factor convert video assist anal fistula treatment vaaft seton fistulotomi materi method total patient regist undergo vaaft januari june erlonglu hospit intraop examin fistula tract reveal patient assign undergo vaaft oper seton fistulotomi result among patient age year underw intraop examin fistula tract complet standard vaaft convert seton fistulotomi univari analys reveal age necrot caviti diamet cm scar anal entranc tissu edema park classif fistula stenosi fistula branch signific differ vaaft convert group p multivari analysi reveal signific correl risk surgeri convers presenc necrot caviti diamet cm odd ratio confid interv ci p scar anal entranc ci p fistula stenosi ci p fistula branch ci p nomogram base logist model fit high accuraci area curv ci conclus independ risk factor convers surgeri vaaft seton fistulotomi presenc necrot caviti diamet cm scar anal entranc fistula stenosi fistula branch protocol systemat review regist priori chines clinic trial registri chictr registr number chictr | D002921;D012003 | T190;T046;T020 |
34,677,096 | minim invas pelvic multiviscer resect approach local advanc primari colorect cancer singl institut experi background role minim invas surgeri mis local advanc colorect cancer crcs suspect direct invas adjac organ structur remain controversi aim studi verifi safeti feasibl minim invas multiviscer resect mvr surgeri local advanc crcs compar convent open surgeri materi method prospect collect data patient underw mvr local advanc crcs retrospect review patient preoper clinic suspect tb stage cancer enrol studi result patient mis open surgeri group respect seven patient mis group requir convers common reason convers uret bladder invas tumor size signific larger open group cm versus cm p wherea mis group includ patient rectal cancer versus p differ observ two group term oper time estim blood loss postop hospit stay curat r resect achiev patient median follow period month year overal surviv mis group open group p year total diseas free surviv dfs respect p three year local dfs mis group open group p conclus mis primari tb crcs without urinari tract invas safe feasibl | D015179;D010535 | T061;T191;T060 |
34,677,095 | health profil preterm male duchenn muscular dystrophi retrospect cohort studi character health profil preterm male duchenn muscular dystrophi major clinic mileston ambul cessat assist ventil use onset left ventricular dysfunct corticosteroid use male duchenn muscular dystrophi identifi popul base surveil system analyz use kaplan meier surviv curv cox proport hazard model adjust risk receiv respiratori intervent among preterm male duchenn muscular dystrophi higher among correspond full term male duchenn muscular dystrophi adjust risk ambul cessat left ventricular dysfunct modest elev among preterm compar full term male confid interv contain null differ start corticosteroid use preterm full term duchenn muscular dystrophi male observ overal diseas cours seem similar preterm full term male duchenn muscular dystrophi howev pulmonari function seem affect earlier among preterm male duchenn muscular dystrophi | D006304 | T080 |
34,677,094 | technic expertis necessari assess technic expertis let ask kid background simul increas role surgic train howev use valid tool object structur assess technic skill osat time consum may potenti barrier simul base train studi test hypothesi assessor technic expertis necessari object score technic task method three task ring transfer needl pass atresia cut perform use synthet thoracoscop simul esophag atresiatracheoesophag fistula three pediatr surgeon novic adult children age year score attempt use overal global osat rate repeat awkward movement fluid movement awkward result ring transfer assessor score novic particip signific less expert intermedi score surgeon p nonsurgeon adult p children p needl pass assessor gave signific differ score novic expert surgeon p nonsurgeon adult p children p atresia cut surgeon assessor gave signific higher score expert intermedi novic p nonsurgeon assessor gave expert intermedi signific higher score novic p surgeon assessor achiev good reliabl ring transfer needl pass compar nonsurgeon assessor show poor reliabl ring transfer moder needl pass conclus expertis perform procedur prerequisit assessor evalu technic skill henc assessor skill acquisit nonexpert nonsurgeon even child variabl group suggest reliabl overal increas multipl assessor although nonsurgeon assessor may appropri format assess lack reliabl provid assess compet high stake complex task summat assess like requir least surgeonexpert assessor provid reliabl | D004933;D000066908 | T065;T019 |
34,677,092 | pair fasten techniqu bolster free gastropexi laparoscop gastrostomi tube placement purpos gastropexi laparoscop gastrostomi tube gt insert technic challeng fasten effect method gastropexi howev use extern bolster requir addit procedur remov may caus skin complic due pressur necrosi describ experi util fasten novel way elimin extern bolster laparoscop gt placement method pediatr patient requir enter access underw gastrostomi singl institut use pair fasten techniqu review gastropexi achiev pass pair fasten laparoscop andor endoscop guidanc singl stab incis stomach squar configur allow sutur one fasten tie subcutan pair sutur elimin need extern bolster oper time day postop complic includ local wound infect granul tissu format bleed tube replac report result thirti patient underw gastrostomi placement use pair fasten techniqu mean age year standard deviat sd mean weight kg sd mean tube length cm sd eight patient underw addit procedur time gastrostomi mean oper time minut sd five patient develop local wound infect requir antibiot five develop granul tissu seven patient underw tube replac within day dislodg stem upsiz conclus pair fasten techniqu safe effici method primari button gastrostomi placement method elimin need addit trocar extern bolster may help patient thick abdomin wall | D059485;D010535 | T060;T061 |
34,677,089 | greater uptak altern reimburs methodolog need realiz cost save potenti oncolog biosimilar unit state background biolog import treatment option solid tumor hematolog malign primari driver health care spend growth unit state yet realiz promis reduc cost via biosimilar slow uptak partial result commerci payer reimburs model creat econom incent favor prescrib refer biolog object examin econom feasibl altern reimburs methodolog prospect share save across commerci payer provid shift econom incent favor lower cost oncolog biosimilar method use oncolog monoclon antibodi drug trastuzumab bevacizumab rituximab exampl develop altern reimburs model would offer addit per unit payment extra consider provid net incom per unit biosimilar refer biolog becom equal provid negoti rate payer allow amount averag sale price obtain claim data project develop pricescost scenario analys vari key model assumpt perform result altern reimburs model achiev year year payer save commerci market drug site servic analyz base analysi show first year cost save payer net cost share physician offic pos non b hospit outpati depart hopd patient use drug analyz five year cumul save per patient rang po hopd payer save vari depend characterist provid payer negoti eg lower vs highermarkup provid pos vs hopd conclus posit payer save shown model suggest altern reimburs arrang could facilit econom compromis wherein commerci payer save biosimilar provid incom preserv disclosur research fund provid pfizer inc yang shelbaya employe pfizer inc pfizer stock carioto pyenson smith jacobson pitting employe milliman inc receiv research fund pfizer inc work studi milliman inc provid actuari profession servic organ throughout healthcar industri none conting equiti invest relationship | D008495;D012051 | T091;T170 |
34,677,088 | econom impact appli aasld idsa simplifi treatment algorithm real world manag hepat c background american associ studi liver diseas aasld infecti diseas societi america idsa recommend may patient hepat c virus hcv could assess treatment initi simplifi treatment algorithm approach use standard blood fibrosi test rather genotyp test guid initi pan genotyp direct act antivir agent daa sofosbuvirvelpatasvir sofvel glecaprevirpibrentasvir glepib treatment object compar health care resourc util hcru cost patient initi treatment via simplifi vs nonsimplifi algorithm genotyp test method identifi adult commerci medicar advantag coverag diagnos hcv initi sofvel glepib juli august nation repres us administr claim databas index date defin first pharmaci sofvel glepib fill date continu enrol month month index date requir patient claim hepat b hiv decompens liver prior daa exclud patient propens score match group simplifi nonsimplifi hcv relat hcru cost compar post match group result hcv patient includ initi sofvel glepib via simplifi algorithm pre match treatment sofvel glepib half sofvel glepib patient start treatment via simplifi algorithm hcv patient initi via simplifi algorithm like male vs p commerci insur vs p midwest vs p vs nonsimplifi patient nonsimplifi group liver diseas vs p metabol disord vs p dyslipidemia vs p vs simplifi group index prescript written gastroenterolog infecti diseas specialist simplifi vs nonsimplifi specialist visit within day prior index daa fill p match result well match patient group post match baselin simplifi treatment group signific lower median interquartil rang iqr hcv relat medic health care cost vs match nonsimplifi group vs p median noninpatientemerg depart health plan paid cost also signific lower simplifi cohort vs p follow medic hcv relat health care cost similar across group conclus studi compar econom outcom hcv treatment initi via simplifi nonsimplifi algorithm simplifi approach result lower use health care resourc greater cost save greater abil patient access care specialist nonspecialist provid addit studi need earli find suggest feasibl path simplifi hcv treatment real world manag care set disclosur fund support studi provid gilead scienc inc majethia lee mozaffari wolf hsiao employe gilead scienc inc bunner chastek employe optum life scienc receiv fund gilead scienc inc conduct studi bunner own stock unitedhealth group parent compani optum poster base select data studi present amcp virtual meet april | D000465;D005102;D010342;D012952 | T092;T055;T170;T094;T081;T058;T080 |
34,677,087 | diagnost delay adolesc cancer covid pandem new price patient pay worldwid coronavirus diseas pandem caus wors chanc time diagnosi cancer patient conduct retrospect analysi new diagnos regist nation pediatr oncolog databas compar first lockdown period march may period total number case year drop major reduct observ adolesc year adolesc solid tumor p data suggest enforc lockdown reduc possibl alreadi vulner patient access referr center | D000086382;D009369 | T191;T047;T067 |
34,677,084 | platelet proteom dynam hibern line ground squirrel hibern mammal undergo dramat drop temperatur blood flow torpor yet avoid stasi blood clot mechan remain unspecifi effect hibern hemostasi especi complex cold temperatur general activ platelet result platelet clearanc cold storag lesion context blood transfus hibern bodi temperatur c c line ground squirrel ictidomi tridecemlineatus provid model studi hemostasi well platelet cold storag lesion resist hibern quantifi systemat compar proteom platelet collect ground squirrel summer activ fall entranc winter topor elucid molecular level chang platelet may support hemostat adapt torpor platelet isol total squirrel june octob januari platelet lysat anim digest trypsin prior plex tandem mass tag tmt label follow lc msms analysi relat protein quantif measur protein signific variat abund platelet cours entranc torpor activ includ system protein regul translat secret metabol complement coagul cascad also note speci specif differ level hemostat secretori inflammatori regul ground squirrel platelet relat human platelet altogeth provid first ever proteom character platelet hibern anim systemat chang metabol hemostat protein may account physiolog adapt torpor also inform translat effort improv cold storag human platelet transfus | D012621 | T079 |
34,677,082 | larg scale omic data reveal cooper mutat circrna mirna target gene network liver cancer oncogenesi aim clarifi initi trigger differenti express gene cancer help research understand cellular system whole network materi method retriev transcriptom translatom tumor normal tissu ten liver cancer patient defin differenti express gene tumor specif mutat associ oncogenesi mutat target predict experiment verif result upregul gene tumor specif mutat utr abolish bind mirna downregul gene correspond mirna mutual target two circrna mutat base pair region transfect experi support oncogen role mutat conclus tumor specif mutat serv initi trigger liver cancer mutat circrna mirna target gene chain complet | D015972;D053263 | T044;T045 |
34,677,081 | pilot random control trial fitbit facebook base physic activ intervent young adult cancer survivor purpos young adult cancer survivor yac meet physic activ pa guidelin although pa improv health qualiti life qol random control trial rcts pa intervent yac exist conduct pilot rct test feasibl pa intervent among yac method recruit year old year postcanc therapi seattl cancer care allianc week intervent involv wrist worn pa track devic fitbit peer base facebook support group step count goal set self select support buddi control receiv fitbit baselin assess occur random follow assess occur intervent week feasibl criteria list exploratori outcom includ pa sedentari time st qol measur eg fatigu self determin theori sdt construct measur result feasibl criteria met recruit yac intervent particip wore fitbit major intervent day particip complet questionnair baselin follow exploratori analys adjust wave acceleromet wear time race incom show signific group differ chang st vs minutesday p chang moder vigor intens pa vs minutesday p compar intervent particip control intervent vs control group greater increas fatigu interfer p signific differ sdt qol measur found conclus fitbit facebook base pa intervent feasibl yac promis effect reduc st warrant fulli power rct clinic trial registr nct | D000073116;D009369;D061108 | T191;T170;T101;T201 |
34,677,080 | robot vessel sealer devic lymphocel prevent pelvic lymphadenectomi result random trial introduct pelvic lymph node dissect plnd robot prostatectomi associ potenti complic common complic plnd lymphocel occur patient studi screen imag usual asymptomat perform prospect random trial evalu whether use advanc bipolar energi plnd via robot vessel sealer prevent lymphocel method total patient enrol trial patient serv control robot plnd random perform use vessel sealer one side standard plnd use clip side patient underw screen comput tomographi scan month postop radiologist blind assign techniqu signific lymphocel defin fluid collect cm plane result enrol complet studi mean nodal yield node versus node vessel sealer side versus standard techniqu p respect mean oper time plnd versus minut p respect twenti two lymphocel identifi ten occur vessel sealer side versus standard side versus p lymphocel asymptomat conclus robot advanc bipolar devic appear prevent lymphocel vessel sealer also increas rate lymphocel compar standard techniqu use clip techniqu equal efficaci effici safe plnd surgeon prefer avoid clip reason use vessel sealer although increas cost clinic trial registr number nct | D008210;D065287 | T047;T061 |
34,677,079 | profil obstetr outcom teenag pregnanc compar pregnant adult district hospit kwazulu natal teenag pregnanc remain major public health concern challeng develop countri young matern age lead serious physic social psycholog consequ teenag mother less like gain full educ potenti higher risk poverti complic pregnanc object studi describ profil obstetr outcom teenag pregnanc compar pregnant adult district hospit kwazulu natal | D015658;D011253 | T040;T033;T047 |
34,677,078 | malnutrit children age year primari health care set studi outlin type malnutrit amongst children caus malnutrit intervent primari health care level recommend allevi childhood malnutrit south africa | D015362;D044342 | T047 |
34,677,077 | preanaesthet assess manag context district hospit preanaesthet assess manag allow systemat identif periop risk implement intervent mitig patient physiolog state optimis surgeri procedur crucial activ good periop outcom patient assess higher risk unanticip advers periop event like receiv suboptim manag district hospit south africa perform minor moder complex surgic procedur requir anaesthesia administ most healthi patient stabl diseas without function limit signific proport anaesthesia relat death report district hospit link poor risk assess manag articl highlight key clinic imper optim preanaesthet assess manag district hospit perspect | D000758;D000776 | T091;T061 |
34,677,076 | updat programmat learn outcom train famili physician south africa train medic specialist constant align need popul health system nation educ train committe south african academi famili physician reach consensus updat programmat learn outcom train specialist famili physician south africa learn outcom first develop guid train programm special recognis fifteen year later time revisit revis learn outcom learn outcom defin famili physician abl end year postgradu train revis present five unit standard programmat exit level learn outcom | D002983;D010821 | T097;T080 |
34,677,069 | organ photo antimicrobi principl molecul design applic emerg multi drug resist pathogen threaten healthcar system world wide recent advanc phototherapi pt approach mediat photo antimicrobi pam provid new opportun current serious antibiot resist pt treatment reactiv oxygen speci heat produc pam would react cell membran consequ leak cytoplasm compon effect erad differ pathogen like bacteria fungi virus even parasit perspect concentr develop differ organ photo antimicrobi opam applic practic therapeut agent therapi local infect wound dress remov biofilm medic devic also discuss design high effici opam modifi chemic structur conjug target compon moreov perspect provid discuss general challeng direct opam need done hope overview opam prosper wide use microbi infect futur especi time global covid epidem get serious | D015195 | T090 |
34,677,067 | simpl rapid synthesi branch peptid microwav assist bead ligat rapid bead converg method prepar branch peptid report linear peptid prepar dbz resin ligat various branch core includ lysin dendron dendrit compound alongsid microwav irradi equiv peptid suffici afford yield pure branch peptid without chromatograph purif remark desir compound prepar within hour | D008872;D010455 | T070;T116;T057;T121 |
34,677,059 | recent advanc enantioselect synthesi chiral amin via transit metal catalyz asymmetr hydrogen chiral amin key structur motif present wide varieti natur product drug biolog activ compound past decad signific advanc made respect enantioselect synthesi chiral amin mani base catalyt asymmetr hydrogen ah present review cover use ah synthesi chiral amin bear stereogen center either posit respect nitrogen atom report therefor provid overview recent advanc ah imin enamid enamin allyl amin n heteroaromat compound | D000588;D028561 | T196;T109 |
34,677,057 | direct write pattern biomimet lipid membran situ fluidfm creation biolog inspir artifici membran substrat custom size close proxim provid platform studi biolog process simplifi manner also constitut build block chemic biolog sensor integr microfluid devic scan probe lithographi tool dip pen nanolithographi dpn open new paradigm regard although possess inher drawback like need oper air environ limit choic lipid pattern work propos use fluid forc microscopi fluidfm technolog fabric biomimet membran without lose multiplex capabl dpn gain flexibl lipid ink pattern environ shed light drive mechan fluidfm mediat lithographi process air liquid obtain result prompt creation realist biomimet membran arbitrari complex phospholipid mixtur cholesterol potenti function membran protein direct pattern physiolog environ | D036103 | T090 |
34,677,054 | thpacc act posit regul homodimericin biosynthesi antifung activ trichoderma harzianum palrim pathway key transcript factor pacc play import role fungal adapt ambient ph regard growth secondari metabol virul howev effect pacc secondari metabol import biocontrol fungus trichoderma harzianum remain elus answer question thpacc delet ko thpacc overexpress oe thpacc mutant harzianum construct transcriptom analysi harzianum ko thpacc suggest thpacc act posit negat regul secondari metabolit sm product investig reveal delet thpacc abolish homodimericin epi homodimericin product moreov thpacc play role antagon harzianum sclerotinia sclerotiorum epi homodimericin demonstr moder inhibitori activ sclerotiorum result contribut deeper understand thpacc function sm product antifung activ harzianum | D001203;D014242 | T004 |
34,677,053 | screen print tissu model use chemic cross link hydrogel system simpl approach effici make high tunabl matric vitro model provid good start point drug screen understand various cellular mechan correspond differ condit cultur drawn signific interest mimic vivo microenviron better overcom limit monolay cultur previous report techniqu base screen print process pattern live mammalian cell use gelatin bioink even though gelatin inexpens scaffold materi various tissu engin applic might ideal hydrogel materi provid various mechan chemic cue cell paper discuss synthesi character two synthet chemic cross link hydrogel system base poli ethylen glycol peg poli l lysin pll use bioink screen print process hydrogel suitabl bioink screen print process serv barebon materi tune mechan augment chemic creat suitabl vitro microenviron cell paper present synthesi mechan test character hydrogel system applic screen print process | D062028;D020100 | T122;T063 |
34,677,048 | small smart ldlr specif micell augment sorafenib therapi glioblastoma target molecular therapi exampl sorafenib sf consid new potent strategi glioblastoma gbm remain hard treat today sever clinic trial sf monotherapi combin therapi current treatment met clinic endpoint like result blood brain barrier bbb inferior gbm deliveri design explor small smart ldlr specif micell load sf ldlr msf improv sf therapi gbm enhanc bbb penetr gbm accumul cell uptak ldlr msf apo peptid function base poli ethylen glycol poli caprolacton co dithiolan trimethylen carbon mefenam exhibit near quantit sf load small size nm high colloid stabil glutathion activ sf releas vitro vivo studi certifi ldlr msf great enhanc bbb permeabl u mg cell uptak caus fold stronger anti gbm activ fold higher gbm accumul compar free sf non ldlr msf control respect treatment orthotop human gbm tumor model reveal ldlr msf safe dosag mg sfkg signific retard tumor progress improv surviv rate induc tumor cell apoptosi inhibit tumor angiogenesi small smart ldlr specif micell provid potenti solut enhanc target molecular therapi gbm | D001932;D005909 | T191 |
34,677,046 | exploit pglb oligosaccharyltransferas posit negat campylobact jejuni multiproteas digest strategi identifi novel site modifi n link protein glycosyl campylobact jejuni bacteri pathogen encod uniqu n link glycosyl pgl system mediat attach heptasaccharid n sequon contain membran protein pglb oligosaccharyltransferas ost mani target pglb known yet fraction sequon experiment confirm site occup remain elus exploit pglb posit wild type wt negat pglb proteom identifi potenti glycosit nonglycosyl form known glycopeptid typic increas protein normal abund pglb relat wt restor pglb reintroduct pglb pglb sequon contain peptid abund thus consist signific site occup presenc ost peptid novel sequon either unalt like glycosyl show abund consist known glycopeptid topolog analysi reveal unalt sequon often display cytoplasm local despit origin membran protein novel glycosit confirm use parallel multiproteas digest lc msms faim ms defin glycoproteom wt pglb pglb c jejuni identifi glycosit novel site predict proteom valid experiment verifi c jejuni glycosit evid occup nonoccup addit site studi serv model use ost negat cell proteom highlight novel glycosit determin occup rang organ | D016123;D006602 | T007;T116;T126 |
34,677,043 | indic find colonoscopi tertiari hospit north central nigeria seven year review colonoscopi invalu tool use diagnosi colorect diseas also use prevent treatment diseas knowledg prevail colorect diseas key plan prevent | D003113;D015179 | T061;T191;T060 |
34,677,042 | epidemiolog transit econom communiti west african state ecowa evid global burden diseas studi sought explor pattern epidemiolog transit econom communiti west african state ecowa | D000071219;D008017 | T102;T068;T081 |
34,677,041 | preval pattern smoke among health scienc student nnamdi azikiw univers nigeria cigarett group carcinogen major global health concern morbid mortal attribut cigarett smoke prevent health worker health profession student presum well inform smoke therefor absolv menac smoke object studi determin preval pattern smoke among preclin health profession student knowledg health consequ smoke reason smoke | D013334;D014495 | T092;T073;T098;T081 |
34,677,040 | predictor lower extrem amput patient diabet foot ulcer manag outcom diabet foot ulcer associ increas problem among individu diabet aim present studi evalu risk factor amput patient diabet foot ulcer well common caus increas mortal patient | D003920;D017719 | T047 |
34,677,039 | knowledg covid among health care worker nigerian urban communiti willing manag covid patient coronavirus diseas result morbid mortal among contract diseas especi among health care worker hcw involv manag infect patient | D000086382 | T047;T067 |
34,677,038 | long term result head orthosi therapi earli childhood posit relat cranial deform stabil treatment outcom parent satisfact purpos studi determin whether differ type posit relat cranial deform show chang complet head orthosi therapi investig children age begin mold helmet therapi affect durat long term stabil treatment addit parent satisfact helmet therapi investigatedbetween patient analyz undergo helmet therapi begin treatment differ diseas pattern classifi posterior deform plagiocephalus defin cranial vault index cva cm cranial index ci posterior deform brachycephalus defin cva cm ci posterior deform combin plagio brachycephalus defin cva cm ci begin therapi end therapi within year follow ci cva measur three dimension photogrammetri age group month addit parent complet standard questionnair evalu person assess treatment outcomedur treatment ci cva children decreas signific p furthermor ci signific decreas end helmet therapi p cranial vault index decreas signific period p month old group treatment time signific shorter older group start helmet therapi near half parent grade scull moder one third sever deform end treatment major parent report satisfact complianc howev one third parent note slight scull deform person load therapyaft complet therapi improv head shape expect major children particular evid improv ci shorter treatment time age month begin therapi parent report satisfact child complianc almost parent convinc treatment use would repeat | D010549;D049068 | T190;T033;T041 |
34,677,037 | facialtraumasurgeri educ content instagram social media sourc facial trauma surgeri upris influenc social media platform like instagram last decad medic healthcar relat post accumul major particular head face character signifi individu human charact may reason numer post share social media platform purpos investig assess content associ facial trauma surgeri evalu educ qualityth author perform retrospect investig instagram post facialtraumasurgeri due number like comment type post languag purpos sourc furthermor post evalu due educ qualiti examin differ educ levelsth major post show like comment english languag major post type singl photograph multipl photograph video predomin case report sourc post surgeon follow clinic post post rate excel interrat reliabl examin present high concord p studi present analysi quantiti qualiti social media content accord facial trauma surgeri support deduct content instagram share patient unclear sourc thus limit inform nevertheless influenc social media medic inform increas practition face effect patient | D061108;D066231 | T097;T170 |
34,677,036 | uveal malign melanoma hybrid macaw parrot ara chloropterus ara militari adult male green wing ara chloropterus militari ara militari hybrid macaw unknown age present texa veterinari medic teach hospit evalu left periocular swell blepharospasm ocular discharg complet ophthalm examin b mode ocular ultrasonographi perform evalu affect eye ocular examin reveal blind left globe exophthalmo periocular swell diffus corneal edema sever anterior fibrin uveiti obscur visual intraocular structur ultrasound examin reveal hyperecho mass fill posterior segment globe focal discontinu posterior sclera suggest scleral ruptur enucl histopatholog recommend perform month later intraop heavili pigment friabl soft tissu mass extrud posterior sclera extend orbit histolog mass consist malign melanoma patient die hour surgic procedur unknown complic postmortem examin identifi evid metastasi studi describ clinic appear histopatholog find rare ocular neoplasm extrascler extens hybrid macaw although uncommon psittacin bird primari ocular melanocyt neoplasm may display featur malign scleral orbit invas | D005134;D008545;D010311;D012878;D014604 | T191;T012 |
34,677,035 | osseous migrat perfor gastrointestin foreign bodi indian runner duck ana platyrhyncho domesticus indian runner duck ana platyrhyncho domesticus present second opinion linear metal foreign bodi identifi radiograph imag primari veterinarian perform diagnost imag investig present complaint duck left pelvic limb lame imag obtain comput tomographi scan perform second opinion visit reveal linear metal foreign bodi associ migrat tract origin ventriculus termin proxim left femur signific osteomyel note proxim left femur associ presenc linear metal object foreign bodi adhes associ migrat remov stage surgic procedur although penetr ventricular foreign bodi previous report migrat cortex long bone unusu present case demonstr perfor migrat gastrointestin foreign bodi result lame refractori analgesia ancillari support care | D004372;D005547 | T072;T020;T037;T012 |
34,677,034 | success treatment acut craniodors coxofemor luxat scarlet ibi eudocimus ruber use close reduct modifi ehmer sling wherea craniodors displac coxofemor joint common luxat report small larg mammal occur less often avian speci close reduct extern coaptat modifi ehmer sling initi treatment case small anim eg dog cat present coxofemor luxat howev ehmer sling report low success rate treat coxofemor luxat anim intract coxofemor luxat requir open surgic reduct success close reduct coxofemor luxat report avian patient well open reduct surgic techniqu repair avian coxofemor luxat success treatment acut craniodors coxofemor luxat scarlet ibi eudocimus ruber close reduct modifi ehmer sling describ clinic report specif characterist patient injuri thought contribut success case | D006617;D004204 | T190;T037 |
34,677,033 | chronic lymphocyt leukemia cockatiel nymphicus hollandicus year old femal cockatiel nymphicus hollandicus diagnos treat chronic lymphocyt leukemia diagnosi base persist lymphocytosi count increas time refer interv high percentag well differenti lymphocyt bone marrow immunohistochem stain confirm neoplast cell cell origin specif treatment diseas initi withheld commenc base increas lymphocytosi decreas pack cell volum therapeut manag cockatiel chronic lymphocyt leukemia base human protocol treatment chlorambucil stabil diseas result signific regress neoplasm bird euthanat month initi diagnosi month treatment commenc postmortem examin extens cell lymphocyt infiltr found throughout intern organ | D001715;D046410;D015451;D010311 | T191;T047;T012 |
34,677,032 | falcon unit arab emir infect chlamydia psittaci c abortus intermedi specifi chlamydia buteoni polymeras chain reaction chlamydiacea oblig intracellular bacteria broad host rang sever studi found chlamydi speci genet intermedi chlamydia psittaci chlamydia abortus various avian speci one intermedi chlamydia speci found red shoulder hawk buteo lineatus recent classifi new speci chlamydia buteoni newli describ chlamydia speci far report hawk exhibit clinic sign conjunct dyspnea diarrhea present studi fecal sampl gyrfalcon falco rusticolus gyrperegrin falcon hybrid falco rusticolus falco peregrinus falcon unknown speci present falcon clinic arabian peninsula ship vetsuiss faculti univers zurich zurich switzerland examin presenc chlamydiacea step wise diagnost approach perform identifi chlamydi speci involv chlamydiacea detect falcon famili specif real time quantit pcr qpcr identif ribosom rna base microarray assay convent pcr sequenc yield inconclus result indic presenc intermedi chlamydia speci none falcon test posit chlamydia psittaci specif qpcr sampl subject chlamydia buteoni specif qpcr posit sampl detail inform regard clinic histori avail falcon admit falcon clinic dubai unit arab emir six bird present clinic loss perform poor general condit includ vomit diarrhea posit c buteoni bird without clinic diseas sign admit routin health examin posit c buteoni negat yet unknown whether chlamydia buteoni caus diseas bird find studi indic chlamydia buteoni may infecti pathogen falcon speci | D002689;D046428 | T007;T012 |
34,677,031 | survey beak feather diseas virus bfdv guatemalan neotrop psittacin bird beak feather diseas virus bfdv circovirus etiolog agent psittacin beak feather diseas pbfd progress often fatal diseas psittaciform even though neotrop psittacin speci resist clinic infect old world speci bfdv recogn threat immunolog nave wild psittacin flock epidemiolog control paramount conserv effort neotrop speci sampl collect multipl psittacin speci includ ara speci amazona speci white crown parrot pionus senili rescu center guatemala formal psittacin rehabilit reintroduct program total bird adult juvenil unknown sex test bfdv mean real time polymeras chain reaction pcr assay bfdv preval found studi confid interv seven year old scarlet macaw ara macao cyanoptera posit result previous survey convent pcr yield negat result studi suggest complet infect resolut | D001715;D018173;D017925;D011563 | T047;T005;T012 |
34,677,030 | window collis bird brazil epidemiolog factor radiograph necropsi assess bird among visual profici group anim planet howev inabl visual discrimin transluc glass structur result extrem number death worldwid high speed collis despit report avian glass collis north america studi develop understand problem south america none evalu radiograph postmortem find one hundr cadav examin radiograph postmortem data collis report analyz season websit manual report cadav total differ speci bird within famili evalu studi rufous belli thrush turdus rufiventri n ear dove zenaida auriculata n ruddi ground dove columbina talpacoti n common speci migratori speci report sick swift chaetura meridionali small bill elaenia elaenia parvirostri black jacobin florisuga fusca great kiskade pitangus sulphuratus doubl collar seedeat sporophila caerulescen creami belli thrush turdus amaurochalinus male frequent report femal male activ gonad sex unabl determin bird common radiograph lesion note anim loss coelom definit suggest hemorrhag preval postmortem find includ skull hemorrhag encephal contus follow coelom hemorrhag window collis occur spring common breed season avian speci brazil cranioencephal trauma identifi primari caus mortal associ bird fli glass window migrat appear main predispos factor window collis bird brazil increas activ aggress relat breed season especi male may import predispos factor window collis accid | D046109;D020308 | T012 |
34,677,029 | protein electrophoresi serum heparin plasma common mynah acridother tristi although serum protein electrophoresi diagnost tool avail mani veterinari laboratori current refer interv protein fraction healthi common mynah acridother tristi therefor electrophoret pattern protein serum heparin plasma common mynah evalu blood specimen collect healthi adult common mynah unknown age male femal serum total protein protein fraction measur use biuret method follow cellulos acet electrophoresi cae serum level albumin compar bromocresol green bcg dye bind cae method four protein fraction includ albumin globulin record electrophoretogram serum specimen sex appear signific effect measur paramet serum bcg albumin fraction signific higher cae albumin fraction p also comparison total protein protein fraction serum plasma specimen bird sampl show total protein cohen index p gamma globulin p total globulin p plasma sampl signific higher serum sampl result studi provid specif refer interv total protein protein fraction common mynah essenti proper interpret laboratori result also reveal albumin measur bcg method yield unreli result common mynah | D046749 | T012 |
34,677,028 | evalu atherosclerot lesion risk factor atherosclerosi raptor northern california atherosclerosi chronic inflammatori diseas report affect cardiovascular system mani avian speci howev atherosclerosi raptor speci fulli evalu aim studi histolog character central peripher atherosclerot lesion raptor submit patholog servic northern california also evalu risk factor includ age gender origin avian famili atherosclerot lesion categor minim mild moder sever base sever lesion distribut within arteri wall among central arteri lesion determin greater sever aorta pulmonari arteri peripher arteri affect includ myocardi coronari arteri kidney gonad splenic arteri howev hepat pulmonari arteri uncommon affect atherosclerosi diagnos raptor speci repres famili accipitrida cathartida falconida strigida overal preval ci atherosclerosi raptor rang falconida highest preval rang detect tytonida pandionida famili multipl logist regress model joint account differ risk famili age gender found risk accipitrida signific less falconida adult raptor greater risk atherosclerot lesion juvenil femal frequent affect male | D050197;D020304 | T047;T012;T046 |
34,677,027 | pharmacokinet singl intramuscular inject ceftiofur crystallin free acid bald eagl haliaeetus leucocephalus object studi evalu pharmacokinet properti ceftiofur crystallin free acid ccfa administ intramuscular dosag mgkg bald eagl baea haliaeetus leucocephalus ceftiofur crystallin free acid long act inject third generat cephalosporin antibiot drug prospect random complet crossov design use pharmacokinet investig ccfa mgkg administ intramuscular blood sampl obtain adult nonreleas healthi baea predetermin sampl time week washout period protocol repeat bird receiv dose given initi sampl collect accord random crossov design plasma ceftiofur free acid equival quantifi data analyz noncompartment pharmacokinet approach mean observ peak plasma concentr gml gml mgkg ccfa im administr respect mean observ time maximum plasma concentr hour mean termin elimin half life hour intramuscular administr mgkg ccfa respect baea report minimum inhibitori concentr raptor bacteri isol prior studi use determin target minimum inhibitori concentr gml select investig previous publish inform target plasma concentr gml determin ccfa baea result studi ccfa may dose everi hour mgkg im everi hour mgkg im baea | D002511;D020307 | T195;T109;T012 |
34,677,026 | emerg pathogen gammaproteobacteria wohlfahrtiimona chitiniclastica ignatzschineria speci turkey vultur cathart aura new world vultur turkey vultur cathart aura oblig scaveng larg geograph rang preliminari character turkey vultur tv gastrointestin microbiom southern california identifi recent describ emerg bacteri pathogen previous known associ avian speci high throughput sequenc broad rang rrna gene amplicon reveal sequenc tv cloacal swab relat closest wohlfahrtiimona chitiniclastica ignatzschineria speci gammaproteobacteria consid unit state center diseas control prevent emerg zoonot pathogen none bacteri sequenc type previous identifi sampl obtain turkey vultur gastrointestin microbiom use bioinformat workflow previous establish research group design specif sensit polymeras chain reaction primer set repres novel diagnost assay genera wohlfahrtiimona ignatzschineria primer set valid sanger sequenc confirm complex tv sampl genera wohlfahrtiimona ignatzschineria known dipteran host molecular diagnost tool present use better understand role fli vultur scaveng ecolog epidemiolog genera wohlfahrtiimona ignatzschineria one health perspect | D004827;D020563 | T033;T007;T047 |
34,677,025 | induct general anesthesia alfaxalon domest chicken alfaxalon safe effect anesthet drug induct general anesthesia mani nonavian companion anim speci howev efficaci fulli evalu bird premed trial chicken sedat butorphanol mgkg intramuscular midazolam mgkg intramuscular minut intraven administr alfaxalon chicken classifi anesthet endotrach intub achiev without elicit cough reflex provok patient resist minim glotti movement within second administr alfaxalon qualit quantit data record includ durat anesthesia qualiti induct qualiti recoveri reflex time sternal recumb time stand time normal behavior surviv analysi use analyz associ alfaxalon dosag premed time relat variabl evalu dose lowest intraven alfaxalon dose requir achiev anesthet induct endotrach intub unpremed premed chicken mgkg respect durat anesthesia dose rate within studi rang second minut second premed general improv qualiti induct recoveri signific p increas time requir chicken stand anesthet return normal behavior chicken exhibit vari degre hyperact anesthet induct recoveri postinduct apnea death subject bird occur investig | D002645;D011277 | T109;T012 |
34,677,024 | avian sedat use procedur sedat bird becom routin practic veterinari medicin past year correspond increas avian sedat research sedat often use clinic set bird facilit examin andor diagnost sampl collect splint applic groom minor surgic procedur sedat provid sever benefit manual restraint general anesthesia perform clinic procedur review provid overview current studi avian sedat discuss common indic protocol advers effect sedat avian patient | D000758;D008874 | T121;T061;T109 |
34,677,023 | specul hemoglobin peak posit clinic cation exchang high perform liquid chromatogram diabet blood sampl microarray isoelectr focus hemoglobin c hba c major compon glycat hemoglobin human red blood cell proven signific biomark diagnosi diabet content fresh red cell diabet blood reflect averag level blood glucos previous three month thus hba c level use assess long term glycem control diabet level hba c certifi critic cut diabet diagnosi current common use method hba c quantif base cation exchang high perform liquid chromatographi cx hplc method advantag high stabil rapid autom still unidentifi peak hb speci cx hplc variant system particular presenc hba glutathiol hb affect accur determin hba c hba usual present healthi adult blood sampl concentr hba increas due protect erythrocyt oxid result decreas hba c howev relat locat hba peak cx hplc clinic chromatogram establish address issu extract hb speci fresh blood sampl obtain hospit anaerob environ avoid possibl redox reaction hb glutathion extract hb sampl analyz use two method low resolut cx hplc mm column current use diabet diagnosi high resolut cation exchang hplc mono mm column identifi peak correspond hba cx hplc analysi fresh blood sampl indic unknown peak p locat hba c hba peak correspond hba peak hba c hba mono hplc microarray isoelectr focus ief use micro prepar hba hba c hba healthi blood sampl micro prepar speci hba hba c hba individu identifi via mono hplc result cx hplc mono hplc microarray ief experi indic p peak might correspond hba confirm glutathiol hb sampl synthes via acetylphenylhydrazin analyz use mono cx hplc system result show content glutamin hemoglobin hba mono hplc p cx hplc increas impli peak p retent time min cx hplc peak correspond hba mono hplc microarray ief base experi previous result influenc hba analysi hba c blood sampl diabet diagnosi need consid discuss studi result signific tentat assign peak p offer inform diabet diagnosi use cx hplc clinic set | D003920;D006441 | T116;T047;T123 |
34,677,022 | determin pesticid residu edibl veget oil gas chromatographi time flight mass spectrometri analysi method base gas chromatographi time flight mass spectrometri gc tof ms singl acquisit establish simultan rapid screen accur confirm pesticid residu edibl veget oil first standard librari pesticid establish librari contain gc tof ms inform retent time accur mass measur quantit quantit ion ratio qualit ion accord european union regul sant standard qualit determin hrms determin compound confirm least two ion second instrument condit sampl pretreat condit determin differ pesticid optim follow observ made extract effici acetonitril better acetonitril contain formic acid pesticid recoveri former case rang c psa adsorb exert better purif effect two purif materi c z sep adsorb prime hlb column thus ensur good recoveri target compound pesticid show matrix enhanc effect necessit use matrix match extern calibr method quantit final base find experiment procedur establish edibl veget oil sampl ultrason extract acetonitril result solut subject ot fat remov freez h supernat ml clean dispers solid phase extract use mg c mg psa powder compound separ hp ms ui capillari column mm ioniz use electron impact ion sourc qualit quantit detect pesticid complet full scan mode retent time mass accuraci qualit ion match ratio use qualit screen peak area quantit ion use quantif limit quantif loq pesticid mgkg loq pesticid rang mgkg linear rang loq gl pesticid gl biphenyl correl coeffici greater recoveri pesticid rang three spike level mgkg account total pesticid propos method success appli determin pesticid residu edibl veget oil sampl chlorpyrifo detect six peanut oil sampl bromopropyl fenpropathrin oxadiazon permethrin tebufenpyrad cyproconazol pirimipho methyl detect fourth grade rapese oil sampl result demonstr develop method accur reliabl time save use high throughput screen quantit determin pesticid residu edibl veget oil | D010573 | T131 |
34,677,021 | determin donkey skin ingredi asini corii colla ultra high perform liquid chromatographi tandem mass spectrometri recent year due shortag donkey skin resourc price asini corii colla seen rapid increas consequ fake gelatin prepar hors mule pig cow skin appear market result unreli qualiti asini corii colla therefor urgent need develop effici accur method improv qualiti asini corii colla ultra high perform liquid chromatographi tandem mass spectrometri uhplc msms use determin donkey skin compon asini corii colla accord l g even mix sampl weigh place ml volumetr flask ammonium bicarbon solut ad dissolv sampl solut dilut scale precis ml solut extract ml volumetr flask follow addit ml trypsin solut l mix intern standard work solut mixtur dilut scale use ammonium bicarbon solut shaken place incub h induc enzymolysi constant temperatur mixtur subsequ remov incub cool ambient temperatur filter membran analyz lc ms separ perform uplc system beh c column mm mm gradient elut use acetonitril contain vv formic acid b water contain vv formic acid mobil phase flow rate mlmin column temperatur sampl size l gradient elut condit min b min b b min b b min b min b b min b marker peptid determin posit electrospray ionize esi multipl reaction monitor mrm mode use isotop intern standard method optim enzymolysi condit follow enzymolysi temperatur enzymolysi time h amount enzym ml two marker peptid show good linear rang mgl correl coeffici r greater limit quantit sn mgkg spike level mgkg mgkg mgkg averag recoveri ratio two marker peptid relat standard deviat rsds method favor test actual sampl asini corii colla product compani detect method sum content two marker peptid differ product process raw materi differ sum content sampl averag develop method simpl reliabl reproduc suitabl detect donkey hide compon asini corii colla | D018397;D053719 | T015;T063 |
34,677,020 | develop asymmetr flow field flow fraction system size character starch granul starch occur natur form semicrystallin granul compos two type carbohydr molecul amylos amylopectin ap starch granul starch molecul size rang nm respect size rang among key factor affect function properti starch asymmetr flow field flow fraction af size base separ techniqu major differ af dynam light scatter microscopi techniqu af enabl separ particl base size consequ elut profil convert size distribut sampl last two decad af system coupl onlin multiangl light scatter mal differenti refract index dri detector af mal dri demonstr applic size character starch molecular level unlik size exclus chromatographi sec af system use open channel requir stationari phase pack materi thus shear scission ap molecul af separ minim size detect rang commerci af system rang nm smaller size rang starch granul studi home made af system develop capabl size character starch granul extract sweet potato lotus seed rice investig perform develop af system evalu run mixtur polystyren ps diamet respect baselin separ four ps sampl achiev resolut ps ps detect limit develop af system higher commerci af system thus develop af system promis separ character starch granul effect composit carrier liquid af separ starch granul also studi moreov accuraci af term size character starch granul evalu optic microscopi om result reveal type dispers viscos carrier liquid affect accuraci size character starch granul size distribut rice starch granul obtain use carrier liquid contain wv sodium dodecyl sulfat use dispers wv nan use bactericid wv hydroxypropylmethylcellulos use adjust viscos carrier liquid agreement obtain om furthermor commerci af system coupl mal dri detector employ separ character starch molecul molecular dispers solut necessari reliabl molecular character starch effect starch dissolut temperatur af character starch also investig optim dissolut temperatur lotus seed rice starch granul sweet potato starch granul differ main attribut differ botan origin granul result show ratio radius gyrat r g hydrodynam radius r h rice starch sweet potato starch rang molar mass rang gmol rice starch r g r h ratio rice starch highest appar densiti among three starch indic rice starch molecul dens structur result demonstr af system develop studi rapid accur size character starch granul develop af system combin commerci af system coupl onlin mal dri detector provid technic support studi relationship size nanoscal microscal function properti starch | D031521 | T059 |
34,677,019 | simultan determin volatil perfluorin compound precursor textil use gas chromatographi tripl quadrupol mass spectrometri perfluorin compound pfcs persist organ compound pfcs artifici prepar hydrocarbon hydrogen atom complet replac fluorin pfcs excel thermal stabil chemic stabil high surfac activ hydrophob andor oleophob properti owe except strong c f bond low polariz weak intermolecular van der waal interact current pfcs precursor wide use textil product finish agent surfact recent year increas attent devot pfcs precursor mani countri region european union canada denmark unit state direct regul issu restrict use pfcs precursor number compound list increas continu studi shown pfcs hepatotox embryotox reproduct toxic neurotox carcinogen interfer endocrin system chang anim instinct behavior potenti induc development neurotox human especi young children howev establish method simultan detect multipl pfc precursor necessit particular textil studi method develop simultan determin volatil pfc precursor textil use gas chromatographi tripl quadrupol tandem mass spectrometri gc msms target compound includ four fluorotelom alcohol ftoh three fluorotelom acryl ftas two fluorooctan sulfonamid fosa two fluorooctan sulfonamid ethanol fose studi shown ftoh ftas precursor perfluorocarboxyl acid fosa precursor perfluorooctanesulfon acid pfc precursor convert perfluorocarboxyl acid perfluoroalkyl sulfon acid threaten human health ecolog secur studi effect ultrason assist extract method target compound establish effect extract solvent extract temperatur extract time extract effici investig optimum extract condit develop method carri ultrason extract min methanol extract solvent separ perform vf waxm capillari column mm temperatur program follow target compound detect gc msms multipl reaction monitor mrm mode quantifi use extern standard method matrix effect three textil matric also investig calibr curv volatil pfc precursor show good linear concentr rang gl correl coeffici less limit detect mgkg sn limit quantif mgkg sn recoveri analyt differ textil matrix sampl three spike level rang relat standard deviat rsds n actual sampl analysi four pfc precursor detect textil product sampl method advantag simpl pretreat accur qualit quantit analysi high sensit good reproduc effect use simultan determin volatil pfc precursor textil establish method theoret practic signific control pfc precursor level textil studi offer new test method mitig risk safeti control textil product also provid refer establish test standard pfc precursor textil similar consum good | D053719;D013784 | T063;T073 |
34,677,018 | predict n octanolwat partit coeffici strong ioniz compound ion pair revers phase liquid chromatographi silica base stationari phase n octanolwat partit coeffici log p import paramet character overal hydrophob organ compound revers phase liquid chromatographi rplc recommend effect method indirect determin log p organ econom cooper develop oecd use rplc studi focus determin log p appar n octanolwat partit coeffici log neutral compound weak ioniz compound howev experiment log p log valu strong ioniz compound rare report previous work experiment log strong ioniz compound could determin well ion pair revers phase liquid chromatographi ip rplc octadecyl poli vinyl alcohol column use log log k w ip model establish differ type model compound howev univers strategi differ chromatograph column yet verifi studi retent behavior neutral compound phenol acid carboxyl acid sulfon acid amphoter compound systemat investig silica base c column mm mm via ion suppress rplc rplc ip rplc respect rplc mode methanol mmoll ammonium dihydrogen phosphat buffer ph use mobil phase perform isocrat elut differ methanol ratio log k w valu test compound obtain use linear solvent strength lss model neutral compound weak ioniz phenol acid benzen carboxyl acid use model compound establish log log k w model quantit structur retent relationship qsrr model includ structur relat descriptor like charg n e abraham solvat paramet b exhibit much better correl unari linear regress model log log k w log log ph valu ioniz compound determin model determin compound use model compound valid compound ip rplc ip rplc mode besid methanol ammonium dihydrogen phosphat buffer mobil phase also contain tetrabutylammonium bromid ion pair reagent retent behavior test compound conform well lss model even ip rplc log k linear correl coeffici r greater log log k w ip model establish use compound mix model set includ neutral weak ioniz strong ioniz compound similar introduc n e b log log k w ip model show good linear r greater compar log log k w ip model establish silica base c column work establish poli vinyl alcohol base c column previous work n e b contribut model work indic greater secondari effect silica base column confirm reliabl log log k w ip model three differ type acid compound use valid compound predict log three ionic compound similar determin shake flask method sfm slow stir method ssm rplc method work confirm reliabl model base result log valu eight strong ioniz compound predict ip rplc find suggest ip rplc promis method predict experiment log strong ioniz compound convent silica base c column offer flexibl option log determin | D056148;D014867 | T059;T121;T197 |
34,677,017 | determin dye oxid hair dye product high perform liquid chromatographi oxid hair dye product alway one key concern cosmet supervis various aromat amin phenol dye use product differ degre sensit toxic therefor necessari establish rapid accur method determin various dye high perform liquid chromatographi hplc method develop determin dye oxid hair dye product method optim term mobil phase type column temperatur detect wavelength extract solvent concentr sampl pretreat method follow weigh g sampl accur ad ml sodium bisulfit solut contain ethanol extract ultrason min ad ml sodium bisulfit solut chromatograph separ carri water atlanti mv kit column mm mm gradient elut protect column sampl solut filter use syring filter membran inject mobil phase moll ammonium acet aqueous solut contain acetonitril acetonitril column temperatur vari separ dye detect use photodiod array detector detect wavelength dye nm nine dye nm extern standard method use quantit analysi result show dye could separ well dye good linear concentr rang correl coeffici r exceed limit detect lod dye rang gg limit quantif loq rang gg averag spike recoveri three level mgg dye rang relat standard deviat rsds less stabil dye standard solut good within h rsds rang demonstr applic method batch commerci oxid hair dye product differ manufactur analyz total kind dye detect batch sampl content dye rang method great increas type dye detect singl chromatographi step especi permit dye type compar standard method safeti technic standard cosmet edit method replenish permit dye hydroxyethyl diaminopyrazol sulfat hydroxyethyl p phenylenediaminesulf tetraaminopyrimidin sulfat dihydroxyethylaminotoluen amino chloro nitrophenol methyl hydroxyethylaminophenol nitro p hydroxyethylaminophenol hydroxypropylamino nitrophenol amino chloro cresol amino chloro cresol hc yellow hydroxybenzomorpholin hydroxyethyl nitro p toluidin sensit accuraci result could ensur detect effici could improv valid method develop method suitabl determin various dye oxid hair dye product provid effect technic mean supervis product | D003358;D006202 | T167;T120;T073 |
34,677,016 | determin plant growth regul anim deriv food use quecher isotop label intern standard high perform liquid chromatographi tandem mass spectrometri among wide use pesticid agricultur plant growth regul pgrs posit influenc plant howev overus pgrs may induc toxic food even hazard human health numer studi investig presenc residu pgrs veget fruit anim deriv food one domin food sourc provid nutrient fulfil daili dietari intak could also potenti contamin pgrs howev littl inform pgr residu anim deriv food standard also lack among techniqu pgr determin anim deriv food therebi restrict establish pesticid usag food safeti regul therefor studi rapid effect method analyz chlormequat chlorid thidiazuron paclobutrazol anim deriv food sampl establish method primarili involv high perform liquid chromatographi tandem mass spectrometri combin use isotop label intern standard extract clean procedur base quecher method analyt extract pork beef chicken pork liver egg milk sampl use acetonitril follow g anhydr magnesium sulfat mgso g sodium chlorid nacl supernat remov use mixtur mg n propyl ethylenediamin psa mg octadecyl silan c mg mgso pass membran filter determin agil zorbax eclips plus c column mm mm use separ analyt gradient elut program acetonitril mmoll ammonium acet solut mobil phase analyt detect mass spectrometri use posit negat electrospray ionize mode multipl reaction monitor mode matrix match calibr combin intern standard use quantifi pgrs linear regress correl coeffici r pgrs greater correspond linear concentr rang chlormequat chlorid thidiazuron paclobutrazol show good linear rang gl egg pork liver sampl gl pork beef chicken sampl milk sampl thidiazuron paclobutrazol show good linear rang gl chlormequat chlorid show linear rang gl limit detect lod limit quantif loq pgr base signal nois sn ratio optim condit lod rang gkg gkg lod defin amount test compound generat sn ratio higher addit loq rang gkg sn ratio higher precis accuraci evalu recoveri experi loq twice loq time loq mean recoveri rang relat standard deviat rsds rang result indic propos method accur reliabl method modif quecher method advantag owe simplic high sensit use matrix match calibr curv intern standard elimin matrix interfer therebi increas accuraci method method satisfi test requir chlormequat chlorid thidiazuron paclobutrazol residu anim deriv food promis determin pgrs type pesticid anim deriv food | D010937;D053719 | T116;T063;T125 |
34,677,015 | analysi metabolit differ skin clapp favorit mutant red clapp favorit non target metabolom red clapp favorit red mutat cultivar pear cultivar clapp favorit fruit color import featur pear fruit red skin general attract consum anthocyanin chlorophyl carotenoid import pigment color format fruit red color pear skin main due concentr composit anthocyanin metabolom emerg disciplin focus qualit quantit analysi small metabolit low molecular weight biolog cell tissu import part system biolog effect mean solv mani complex biolog problem studi analyz pigment content composit differenti express gene skin green red pear various aspect anthocyanin respons physiolog activ regul pathway aim studi discov differenti metabolit skin clapp favorit red mutat cultivar red clapp favorit metabol compon detect use high perform liquid chromatographi coupl tandem mass spectrometri uplc msms chromatograph experi perform hss column mm mm use mobil phase consist vv formic acid acetonitril water mass spectrometri conduct posit negat mode electrospray ionize esi red clapp favorit clapp favorit collect pear germplasm resourc nurseri yantai institut agricultur scienc shandong data analyz princip compon analysi pca orthogon partial least squar discrimin analysi opl da well cluster analysi heat map first two princip compon exhibit total varianc posit negat ion mode respect pca general reflect metabolit differ two group sampl signific differ metabolit two cultivar result show pls da clear distinguish two group sampl use analyz subsequ differ compon compound identifi base data retriev pmdb databas accord accur mass number secondari fragment isotop distribut result show metabolit content skin red clapp favorit clapp favorit signific differ metabolit p variabl import project vip includ phenol amino acid involv flavonoid metabol amino acid metabol phenyl propanoid biosynthesi metabol pathway includ polyphenol flavonoid amino acid deriv phenylpropan anthocyanin proanthocyanidin flavanol flavonol isoflavon triterpenoid organ acid deriv vitamin organ acid deriv lipid compound chlorogen acid crypto chlorogen acid red clapp favorit time much clapp favorit anthocyanin cornulin glucosid cornulin galactosid time respect phenol epicatechin catechin increas respect content phenylpropan dihydroxycinnam acid red clapp favorit increas time among differenti metabolit metabolit enrich pathway display relationship sampl differ metabolit among differ sampl intuit hierarch cluster heat map analysi perform metabolit express level signific differ enrich pathway kyoto encyclopedia gene genom databas use analyz pathway enrich differ metabolit accord result metabol pathway p flavonoid biosynthesi flavon flavonol biosynthesi phenylpropanoid biosynthesi butano metabol phenylalanin metabol tyrosin metabol plant secondari metabol show complex divers studi would screen pathway affect biosynthesi flavonoid could provid refer studi biosynthesi biolog function flavonoid red fruit studi provid use refer metabolom red pear could provid theoret refer qualiti analysi biolog function research pear | D000872;D053719 | T121;T063;T109 |
34,677,014 | proteom analysi serum serum exosom applic intrahepat cholangiocarcinoma exosom extracellular vesicl diamet rang nm doubl layer lipid membran structur releas various type cell normal abnorm physiolog condit present accord extens biolog function exosom use wide rang research field applic includ potenti biomark drug deliveri vehicl intrahepat cholangiocarcinoma malign tumor biliari epithelium characterist cholangiocellular differenti account type primari liver cancer intrahepat cholangiocarcinoma obvious clinic symptom earli stage result low surviv rate imag equip depend diagnost method current common use diagnost marker low sensitivityspecif necessit develop new specif marker intrahepat cholangiocarcinoma studi exosom isol serum use commerci kit character nanoparticl track analysi western blot analysi transmiss electron microscop analysi prove success isol exosom sodium dodecyl sulfat polyacrylamid gel electrophoresi sds page show protein profil serum serum exosom sampl signific differ particular high abund protein serum sampl signific reduc disappear serum exosom sampl meanwhil protein band may belong exosom appear serum sampl appear serum exosom sampl lead conduc subsequ mass spectrometri analysi serum serum exosom sampl healthi control intrahepat cholangiocarcinoma group analyz liquid chromatographi mass spectrometri label free quantit proteom total protein identifi serum exosom sampl could found exosom protein databas addit credibl protein screen serum serum exosom sampl multi dimension statist analysi differenti protein discoveri unsupervis princip compon analysi supervis orthogon partial least squar discrimin analysi base quantit proteom serum serum exosom sampl could distinguish healthi control intrahepat cholangiocarcinoma group well illustr two type sampl potenti diagnosi intrahepat cholangiocarcinoma upregul downregul protein screen intrahepat cholangiocarcinoma group compar healthi control group base serum sampl upregul downregul protein screen intrahepat cholangiocarcinoma group compar healthi control group base serum exosom sampl four differenti protein screen base two type sampl duplic time differenti express protein screen base serum exosom sampl belong exosom protein databas final biolog inform analysi perform accord differenti protein molecular function biolog process signal pathway enrich differenti protein main involv innat immun respons inflammatori respons blood coagul studi provid refer valu potenti biomark discoveri explor process occurr develop metastasi intrahepat cholangiocarcinoma moreov compar proteom analysi base serum sampl proteom analysi base serum exosom sampl use identifi differenti protein biolog inform although differenti protein biolog inform may show big differ specif sensit exosom base diagnosi superior exosom sampl proteom analysi proven applic valu exosom | D001650;D018281;D055354;D008113 | T026;T191 |
34,677,013 | precis identif link n acetylglucosamin peptid base mesitylenesulfonylhydroxylamin elimin reaction link n acetylglucosamin glcnac import post translat modif protein play essenti role maintain normal biolog activ organ studi shown disrupt glcnac homeostasi close associ various human diseas therefor larg scale enrich identif glcnac protein import explor diagnost biomark clinic diseas glcnacyl substoichiometr glycosid bond unstabl henc enrich identif glcnac protein remain challeng recent metabol label technolog per acetyl unnatur monosaccharid introduc enrich glcnac protein peptid cell howev azidosugar also react thiol group cystein form cystein thiol azidosugar artifici modif byproduct cell metabol interfer identif glcnac protein peptid therefor develop methodolog specif complet remov cystein thiol azidosugar artifici modif necessari mesitylenesulfonylhydroxylamin msh oxid amin reagent great potenti oxid elimin cystein thiol modif dehydroalanin henc worthwhil probe whether msh elimin cystein thiol azidosugar artifici modif two cystein thiol azidosugar artifici modif synthes success incub thiol standard peptid tetraacetyl n azidoacetylgalactosamin ac galnaz sodium carbon buffer mmoll ph min reaction condit msh oxid elimin optim complet remov cystein thiol azidosugar artifici modif sodium phosphat buffer mmoll ph select protect glcnac modif due mild natur extens investig optim reaction condit establish reaction temperatur min reaction time cystein thiol azidosugar artifici modif could remov complet condit furthermor two azid label glcnac n glcnac peptid use assess whether msh destroy glcnac modif time result show two n glcnac peptid stabl treatment msh min short excess msh n glcnac peptid stabl cystein thiol azidosugar artifici modif exhaust sodium phosphat buffer mmoll ph min moreov glcnac modif cystein thiol azidosugar artifici modif exist cell metabol method remov cystein thiol azidosugar artifici modif also ensur stabil glcnac modif grow evid glcnacyl main occur protein cytoplasm nucleus glcnac protein involv import biolog signal pathway nuclear cytoplasm protein incub ac galnaz hela cell select model system nuclear cytoplasm protein digest peptid msh appli remov cystein thiol azidosugar modif addit peptid elimin cystein thiol azidosugar artifici modif identifi indic msh remov interfer cystein thiol azidosugar artifici modif cell metabol biotin probe streptavidin dynabead subsequ use label enrich n glcnaz peptid cell metabol final glcnac peptid attribut protein identifi better understand function role glcnac protein gene ontolog analysi perform cell compon analysi show identifi glcnac protein main distribut inpostsynapt densiti cytoplasm condens nuclear chromosom protein most involv biolog process includ cell divis excitatori postsynapt potenti microtubul base movement protein respons transferas activ transfer acyl group histon acetyltransferas activ microtubul bind high enrich indic glcnac protein play import role cell summari work develop approach enrich glcnac peptid precis metabol label remov cystein thiol azidosugar artifici modif msh methodolog provid new strategi applic metabol label technolog unnatur monosaccharid glycoproteom analysi | D000117;D010455 | T116;T121;T109 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.